More positive Alpharadin data as Algeta/Bayer gear up for approval
This article was originally published in Scrip
Executive Summary
As they await US and European approval for Alpharadin (radium-223) for the treatment of patients with castration-resistant prostate cancer (CRPC) and bone metastases, Algeta and Bayer Healthcare have been publicizing the latest additional sub-analyses from the Phase III ALSYMPCA study investigating the drug.